1. Cellular response to COVID-19 vaccines in hematologic malignancies patients: a new hope for non-responders?
- Author
-
UCL - SSS/DDUV - Institut de Duve, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - SSS/DDUV/SIGN - Cell signalling, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - SSS/IREC/MBLG - Pôle de Microbiologie médicale, UCL - (SLuc) Service de médecine interne générale, UCL - (SLuc) Service de biochimie médicale, UCL - (SLuc) Service de microbiologie, UCL - (SLuc) Service d'hématologie, Saad Albichr, Imane, De Greef, Julien, Van Den Neste, Eric, Poire, Xavier, Havelange, Violaine, Vekemans, Marie-Christiane, Bailly, Sarah, Yombi, Jean Cyr, Mzougui, Samy, Scohy, Anaïs, Kabamba-Mukadi, Benoît, UCL - SSS/DDUV - Institut de Duve, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - SSS/DDUV/SIGN - Cell signalling, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - SSS/IREC/MBLG - Pôle de Microbiologie médicale, UCL - (SLuc) Service de médecine interne générale, UCL - (SLuc) Service de biochimie médicale, UCL - (SLuc) Service de microbiologie, UCL - (SLuc) Service d'hématologie, Saad Albichr, Imane, De Greef, Julien, Van Den Neste, Eric, Poire, Xavier, Havelange, Violaine, Vekemans, Marie-Christiane, Bailly, Sarah, Yombi, Jean Cyr, Mzougui, Samy, Scohy, Anaïs, and Kabamba-Mukadi, Benoît
- Abstract
SARS-CoV-2 vaccines offered great hope in controlling the worldwide COVID-19 pandemic. At present, SARS-CoV-2 vaccines have shown excellent efficacy to prevent COVID-19 but immunocompromised patients were left-off most vaccine clinical trials albeit their extreme vulnerability. Indeed, immunosuppression is associated with a higher risk of developing severe COVID-19 with mortality rates over 30% reported in patients with hematologic malignancies (HM). [...]
- Published
- 2022